Benefits of prostate-specific antigen testing remain unclear

 July 20, 2012 in Cancer It remains unclear whether the benefits of prostate-specific antigen testing outweigh the harms, but evidence suggests that men with a longer life expectancy may benefit from testing, according to a provisional clinical opinion from the American Society of Clinical Oncology published online July 16 in the Journal of Clinical Oncology. (HealthDay) -- It remains unclear whether the benefits of prostate-specific antigen (PSA) testing outweigh the harms, but evidence suggests that men with a longer life expectancy may benefit from testing, according to a provisional clinical opinion from the American Society of Clinical Oncology published online July 16 in the Journal of Clinical Oncology Ethan Basch, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues address the role of PSA testing in the screening of men for prostate cancer. Evidence was considered from a 2011 Agency for Healthcare Research and Quality systematic review on the benefits and harms of screening, and an updated search was conducted to identify additional related evidence. The researchers found that, based on one randomized trial, PSA testing resulted in reduced death rates from prostate cancer, but it was unclear whether the benefits outweighed the screening-associated harms and unnecessary treatment. Evidence suggested that men with longer life expectancy may benefit from PSA testing. For the majority of men, prostate biopsy-associated adverse events were low, but increasing rates of infectious complications after biopsy were noted in several population-based studies. "At this point in time, it is uncertain whether the benefits associated with PSA testing for prostate cancer screening are worth the harms associated with screening and subsequent unnecessary treatment," the authors write. "Because the evidence does not clearly inform the issue around PSA-based screening and its downstream effects, the importance of informed and shared decision making becomes paramount." One author disclosed financial ties to GlaxoSmithKline and Genomic Health. More information: Abstract Full Text Journal reference: Journal of Clinical Oncology